MAP3K14 and metabolic disease: Another meta-analysis detected that supplementary selenium with a daily dosage of 200 μg/d in patients with metabolic diseases could clearly connect to a decrease in high-sensitivity C-reactive protein (hs-CRP, SMD: −0.44, 95% CI: −0.67, −0.21), which indicates a reduced grade of inflammation in the body (47).